First Manhattan
CERE

First Manhattan’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

First Manhattan’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$4.23K – 1388
2024
Q1 		$4.23K Hold
100
– – ﹤0.01% 1212
2023
Q4 		$4.24K Hold
100
– – ﹤0.01% 1215
2023
Q3 		$2.18K Buy
+100
New +$2.5K ﹤0.01% 1307

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

First Manhattan's CERE Position: Q2 2024 in Review

First Manhattan sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 100 shares — an estimated $4.23K sold.

First Manhattan first reported a position in CERE in Q3 2023 and held it in 3 quarters. The position peaked at $4.24K in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • First Manhattan reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 100 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $4.23K.
  • First Manhattan first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
  • First Manhattan's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.24K in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.